TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12741307

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - enoxaparine (100 IU/kg twice daily) for an average duration of 13 days, followed by fluindione starting on the fifth day.
Number of subjects: 19
Study: 11107867

Group type: EXPERIMENTAL
Intervention: Gluten free diet (GFD) for 11.7 years
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Gluten free diet (GFD)
Number of subjects: 73
Study: 8869692

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (2.5 mg/kg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1512185

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (maximal BALs of 0.05 or 0.10)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (ascending BALs)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Alcohol treatment (maximal intoxication)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 44
Study: 6861866

Group type: EXPERIMENTAL
Intervention: 100 mg lorcainide tablets taken at 0, 12 and 24 h
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 mg lorcainide tablets taken at 0, 1, 12 and 24 h
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 mg lorcainide tablets taken at 0, 2, 12 and 24 h
Number of subjects: 25
Study: 30755027

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention group
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Overall treatment satisfaction
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Overall quality of life
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Angina frequency
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Physical limitation scale
Number of subjects: 1261

Group type: EXPERIMENTAL
Intervention: Sex differences in physical limitations
Number of subjects: 1261
Study: 29048455

Group type: EXPERIMENTAL
Intervention: Intervention group (games focusing on food pyramid and physical activity)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (informative session about food pyramid and physical activity)
Number of subjects: 89
Study: 26140541

Group type: EXPERIMENTAL
Intervention: Carbohydrate (maltodextrin)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Lipid (dairy-cream)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 33
Study: 24787767

Group type: EXPERIMENTAL
Intervention: Restore intervention
Number of subjects: 83
Study: 22647148

Group type: EXPERIMENTAL
Intervention: media-supported 4-step approach
Number of subjects: 220

Group type: COMPARATOR
Intervention: standard 4-step approach
Number of subjects: 220
Study: 19270819

Group type: EXPERIMENTAL
Intervention: Fibrin glue (sprayed onto the axillary dissection site)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 100
Study: 17900408

Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rilmazafone (2 mg/day)
Number of subjects: 42
Study: 15482064

Group type: EXPERIMENTAL
Intervention: Dimensional theory applied to recognition of celebrity faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dimensional theory applied to recognition of unfamiliar faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear theory applied to recognition tasks
Number of subjects: 0
Study: 11525272

Group type: COMPARATOR
Intervention: Raloxifene hydrochloride, 60 mg/d for 6 months
Number of subjects: 29
Study: 9801723

Group type: EXPERIMENTAL
Intervention: Dual Focus Schema Therapy (manual-guided individual cognitive-behavioral therapy) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12-Step Drug Counseling
Number of subjects: 0
Study: 7949701

Group type: EXPERIMENTAL
Intervention: Zygapophysial joint injections or blocks of the medial branches of the dorsal ramus with lignocaine
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Confirmatory blocks using bupivacaine
Number of subjects: 176
Study: 2897433

Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 497

Group type: COMPARATOR
Intervention: FAC (fluorouracil, doxorubicin, cyclophosphamide)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: FEC
Number of subjects: 497

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 497
Study: 29564750

Group type: EXPERIMENTAL
Intervention: Topical dressing formulated with 0.1% P1G10
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hydrogel (control)
Number of subjects: 50
Study: 27792728

Group type: EXPERIMENTAL
Intervention: Pharmacological manipulation of catecholamine activity
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: P3 component of EEG
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: P3 amplitude
Number of subjects: 32
Study: 23801785

Group type: EXPERIMENTAL
Intervention: Active valve circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Leak port circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Leak port circuit with artificial leakage
Number of subjects: 20
Study: 24326198

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (near-infrared light, continuous 850-nm wavelength, power density of 60 mW/cm2 for 20 or 30 min/day or 60 min/week, total energy densities of 72, 108, or 216 J/cm2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (traditional orthodontic treatment without photobiomodulation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 90
Study: 21275167

Group type: EXPERIMENTAL
Intervention: Bizhongxiao Decoction (BZXD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 18163011

Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levothyroxine (L‐T4) (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (euthyroid females)
Number of subjects: 40
Study: 15464664

Group type: EXPERIMENTAL
Intervention: Safe-Cross radiofrequency guidewire
Number of subjects: 116
Study: 11986705

Group type: EXPERIMENTAL
Intervention: Type B inactivated vaccine against HFRS
Number of subjects: 588

Group type: COMPARATOR
Intervention: Control group (no vaccine)
Number of subjects: 588
Study: 9736850

Group type: EXPERIMENTAL
Intervention: 3 minutes study time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 minute 15 seconds study time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30 seconds study time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All expertise levels under constrained processing time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experts' recall under constrained processing time
Number of subjects: 0
Study: 7801390

Group type: EXPERIMENTAL
Intervention: Active laser treatment (40 mW in 60 sec per cm tender tibia edge)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 49
Study: 3294038

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) controlled-release tablets, 300 mg b.i.d.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 30382308

Group type: EXPERIMENTAL
Intervention: Restricted fluid resuscitation regimen
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 27289174

Group type: EXPERIMENTAL
Intervention: Haemopoietic stem-cell gene therapy (HSC-GT) with autologous HSCs transduced with a lentiviral vector encoding ARSA cDNA after busulfan conditioning
Number of subjects: 9
Study: 24715381

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 2-5 years
Number of subjects: 742
Study: 23378751

Group type: EXPERIMENTAL
Intervention: Nurse home visits with alert buttons (NV+AB)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 133
Study: 19934404

Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor (celecoxib; 200 mg/dose, 600 mg total)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor
Number of subjects: 16
Study: 18385262

Group type: EXPERIMENTAL
Intervention: Nasal instillation of midazolam (0.2 mg kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nebulized administration of midazolam (0.2 mg kg(‐1))
Number of subjects: 10
Study: 16780390

Group type: EXPERIMENTAL
Intervention: simvastatin 5 mg/day (n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day (n = 9)
Number of subjects: 27

Group type: COMPARATOR
Intervention: control (usual treatment; n = 8)
Number of subjects: 27
Study: 15144293

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane and high thoracic epidural analgesia
Number of subjects: 30
Study: 11133623

Group type: EXPERIMENTAL
Intervention: Sufentanil 5 microg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sufentanil 10 microg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sufentanil 15 microg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (ropivacaine 0.2% alone)
Number of subjects: 100
Study: 10093379

Group type: EXPERIMENTAL
Intervention: Standard electrode placement procedure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Modified electrode placement procedure
Number of subjects: 80
Study: 7646633

Group type: EXPERIMENTAL
Intervention: Modified Bassini operation
Number of subjects: 265

Group type: COMPARATOR
Intervention: Shouldice procedure
Number of subjects: 265
Study: 3042826

Group type: EXPERIMENTAL
Intervention: High-frequency ventilation (HFV; delivered by Percussionaire VDR 1 at 10 Hz)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV; delivered by a Siemens Servo 900 C)
Number of subjects: 8
Study: 30853012

Group type: EXPERIMENTAL
Intervention: Additional measurement of serum C-reactive protein (CRP)
Number of subjects: 160
Study: 28632527

Group type: EXPERIMENTAL
Intervention: Regional anesthetic block
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 26355647

Group type: EXPERIMENTAL
Intervention: High central load (2-back)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low central load (1-back)
Number of subjects: 0
Study: 24432670

Group type: EXPERIMENTAL
Intervention: PMC therapy combined with LFJC (Langchuang Fuzheng Jiedu Capsule)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PMC therapy combined with LFJC
Number of subjects: 60
Study: 21596725

Group type: COMPARATOR
Intervention: NICE (National Institute for Health and Clinical Excellence)
Number of subjects: 216

Group type: COMPARATOR
Intervention: SIGN (Scottish Intercollegiate Guideline Network)
Number of subjects: 216

Group type: COMPARATOR
Intervention: GRADE (Grading of Recommendations Assessment, Development and Evaluation)
Number of subjects: 216

Group type: COMPARATOR
Intervention: CEBM (Centre for Evidence‐Based Medicine, Oxford)
Number of subjects: 216
Study: 19638231

Group type: EXPERIMENTAL
Intervention: Open-ended questionnaire (A)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Closed-ended questionnaire with deceptive response items (B)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Closed-ended questionnaire with only correct items (C)
Number of subjects: 350
Study: 16211618

Group type: COMPARATOR
Intervention: rTMS (25 Hz)
Number of subjects: 18
Study: 12457031

Group type: COMPARATOR
Intervention: Granisetron (GRN) alone (3 mg/patient)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combination therapy (CCT) with Granisetron (GRN), Methylprednisolone (MPD) (250 mg/patient), and Droperidol (DRP) (0.5 ml/patient)
Number of subjects: 69

Group type: COMPARATOR
Intervention: CMB group (GRN and MPD)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: CCT group
Number of subjects: 69

Group type: COMPARATOR
Intervention: GRN group
Number of subjects: 69
Study: 10657866

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intravenous ceftriaxone
Number of subjects: 70
Study: 9288386

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 58

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 58
Study: 8363290

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: 10% phenylephrine
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: 0.5% tropicamide
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine plus 0.5% tropicamide
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Tropicamide alone or in combination with phenylephrine
Number of subjects: 524
Study: 3092196

Group type: COMPARATOR
Intervention: hGRF 2.5 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF 5 to 80 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF above 80 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF 80 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF 100, 300, and 600 micrograms (subcutaneous administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF 600 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF doses above 80 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: hGRF doses less than 80 micrograms
Number of subjects: 0
Study: 31133040

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity intervention for six months
Number of subjects: 100
Study: 27809592

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Combination of Tamsulosin and Solifenacin
Number of subjects: 260
Study: 25944940

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPAP at 5 cm H2O
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (non-rebreathing face mask)
Number of subjects: 12
Study: 24837026

Group type: EXPERIMENTAL
Intervention: Test to calculate the probability of viability (cases)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Not applicable (controls)
Number of subjects: 69
Study: 22101218

Group type: EXPERIMENTAL
Intervention: Directly Administered Antiretroviral Therapy (DAART)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 154
Study: 19037197

Group type: EXPERIMENTAL
Intervention: Metoprolol in CYP2D6 poor metabolizers (PMs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol in non‐poor metabolizers (non‐PMs)
Number of subjects: 0
Study: 17151339

Group type: EXPERIMENTAL
Intervention: 20 mg/kg rhGAA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 40 mg/kg rhGAA
Number of subjects: 18

Group type: COMPARATOR
Intervention: rhGAA (both doses)
Number of subjects: 18
Study: 15096906

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg or Amlodipine 10 mg (after up-titration)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Valsartan + Hydrochlorothiazide (12.5 mg)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Amlodipine + Hydrochlorothiazide (12.5 mg)
Number of subjects: 164
Study: 11429364

Group type: EXPERIMENTAL
Intervention: 200 mg amantadine IV in 500 mL saline
Number of subjects: 30

Group type: COMPARATOR
Intervention: 500 mL saline IV (Control group)
Number of subjects: 30
Study: 9554288

Group type: EXPERIMENTAL
Intervention: OMV vaccine with aluminium hydroxide and serogroup C-polysaccharide (C-ps)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OMV vaccine without aluminium hydroxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OMV vaccine adsorbed to aluminium hydroxide
Number of subjects: 0
Study: 8052950

Group type: EXPERIMENTAL
Intervention: Low level energy infra-red laser irradiation (4 minutes, total dose = 1J)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ordinary light (control)
Number of subjects: 10
Study: 2648787

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31125171

Group type: EXPERIMENTAL
Intervention: Dermocosmetic treatments
Number of subjects: 36

Group type: COMPARATOR
Intervention: French skin
Number of subjects: 36

Group type: COMPARATOR
Intervention: Brazilian skin
Number of subjects: 36
Study: 31307211

Group type: COMPARATOR
Intervention: Single Anesthetic (SA) - bupivacaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Three Additives (TA) - bupivacaine with buprenorphine, clonidine, and dexamethasone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both SA and TA
Number of subjects: 80
Study: 28404623

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided complete revascularization
Number of subjects: 627

Group type: COMPARATOR
Intervention: Infarct-related percutaneous coronary intervention only
Number of subjects: 627
Study: 25854575

Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 63

Group type: COMPARATOR
Intervention: Ceftriaxone sodium (Control)
Number of subjects: 63
Study: 23812462

Group type: EXPERIMENTAL
Intervention: Daily vaginal dilator use from postoperative weeks 4 through 8
Number of subjects: 60

Group type: COMPARATOR
Intervention: No dilator use (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall sexual function and Patient Global Impression of Improvement scores
Number of subjects: 60
Study: 21168339

Group type: EXPERIMENTAL
Intervention: High-pressure (HP: 80-90 mm Hg)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Low-pressure (LP: 60-70 mm Hg)
Number of subjects: 92
Study: 19583607

Group type: EXPERIMENTAL
Intervention: 1 gm of methylprednisolone before CPB
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard coronary bypass surgery without any additional medication (Control)
Number of subjects: 30
Study: 17210899

Group type: EXPERIMENTAL
Intervention: Lumbar puncture to assess intracranial pressure (ICP)
Number of subjects: 0
Study: 15037052

Group type: EXPERIMENTAL
Intervention: Confabulations of the patient (ES)
Number of subjects: 1
Study: 15630352

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for high-risk patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy for muscle-invasive bladder cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy for metastatic disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multimodality treatment options (operation, chemotherapy, radiotherapy, biology therapy)
Number of subjects: 0
Study: 10037207

Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg BID for 3 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 35
Study: 8746921

Group type: EXPERIMENTAL
Intervention: Daily dosing of 8 mg sublingual buprenorphine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Alternate-day dosing of 8 mg sublingual buprenorphine
Number of subjects: 99
Study: 2286597

Group type: EXPERIMENTAL
Intervention: 200 mg i.v. ofloxacin per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 x 4000 mg piperacillin per day
Number of subjects: 60
Study: 7018639

Group type: EXPERIMENTAL
Intervention: 1 mg of glucagon intravenously
Number of subjects: 91

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 91
Study: 31122037

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention with Advance Care Planning (ACP) education, including interactive decisional support, emotional support, and barrier navigation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC) receiving ACP education alone.
Number of subjects: 0
Study: 30180880

Group type: EXPERIMENTAL
Intervention: Conversational agent with high self-awareness
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Conversational agent with low self-awareness
Number of subjects: 900

Group type: COMPARATOR
Intervention: Wait-list condition with high self-awareness
Number of subjects: 900

Group type: COMPARATOR
Intervention: Wait-list condition with low self-awareness
Number of subjects: 900
Study: 27316539

Group type: EXPERIMENTAL
Intervention: Family-based home health education and blood pressure monitoring by trained female community health volunteers.
Number of subjects: 1638

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 1638
Study: 24600660

Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + β-TCP
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SCTG
Number of subjects: 36

Group type: COMPARATOR
Intervention: CPF
Number of subjects: 36
Study: 22724387

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 870

Group type: COMPARATOR
Intervention: Other anti-epileptic drugs
Number of subjects: 870

Group type: COMPARATOR
Intervention: Migraineurs
Number of subjects: 870

Group type: COMPARATOR
Intervention: Epileptics
Number of subjects: 870

Group type: COMPARATOR
Intervention: Diabetics
Number of subjects: 870

Group type: COMPARATOR
Intervention: Random sample
Number of subjects: 870
Study: 20137764

Group type: COMPARATOR
Intervention: Fasted condition (0% fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low-fat meal (200-300 kcal, ~6% fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate-fat meal (500-600 kcal, ~30% fat)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-fat meal (1,000 kcal, ~50% fat)
Number of subjects: 12
Study: 18048611

Group type: EXPERIMENTAL
Intervention: Smoking Magazine
Number of subjects: 357

Group type: COMPARATOR
Intervention: Non-smoking Magazine
Number of subjects: 357
Study: 16238275

Group type: EXPERIMENTAL
Intervention: 12 mg of Dexamethasone every 12 hours for two doses (Group C, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Group T, n=10)
Number of subjects: 20
Study: 12405303

Group type: EXPERIMENTAL
Intervention: Neurolytic coeliac plexus block
Number of subjects: 30
Study: 10096580

Group type: EXPERIMENTAL
Intervention: anti-IFN-alpha vaccine
Number of subjects: 242

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 242
Study: 7759711

Group type: EXPERIMENTAL
Intervention: Sotalol (n = 54)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Procainamide (n = 73)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Quinidine/mexiletine (n = 49)
Number of subjects: 176

Group type: COMPARATOR
Intervention: ESVEM protocol (compared to standard protocol)
Number of subjects: 176